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Abstract 
A stability indicating reversed phase ultra performance liquid chromatography 
(RP-UPLC) method was developed for simultaneous determination of ambroxol 
hydrochloride (AMB), cetirizine hydrochloride (CTZ), methylparaben (MP) and 
propylparaben (PP) in liquid pharmaceutical formulation. The desired chromato-
graphic separation was achieved on an Agilent Eclipse plus C18, 1.8 µm (50 x 
2.1 mm) column using gradient elution at 237 nm detector wavelength. The 
optimized mobile phase consists of a mixture of 0.01 M phosphate buffer and 
0.1 % triethylamine as a solvent-A and acetonitrile as a solvent-B. The 
developed method separates AMB, CTZ, MP and PP in presence of twelve 
known impurities/degradation products and one unknown degradation product 
within 3.5 min.  Stability indicating capability was established by forced 
degradation experiments and seperation of known and unknown degradation 
products. The lower limit of quantification was established for AMB, CTZ, MP 
and PP. The developed RP-UPLC method was validated according to the 
International Conference on Harmonization (ICH) guidelines. This validated 
method is applied for simultaneous estimation of AMB, CTZ, MP and PP in 
commercially available syrup samples. Further, the method can be extended for 
estimation of AMB, CTZ, MP, PP and levo-cetirizine (LCTZ) in various 
commercially available dosage forms. 526  R. K. Trivedi, M. C. Patel and S. B Jadhav:   
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Introduction 
Ambroxol hydrochloride (AMB) is semi-synthetic derivative of vasicine obtained from 
Indian shrub Adhatoda vasica. It is a metabolic product of bromhexine. It is used as 
broncho secretolytic and an expectorant drug [1]. It simulates the transportation of the 
viscous secretions in the respiratory organs and reduces the stand stillness of the 
secretions. Cetirizine hydrochloride (CTZ) is an orally active and selective H1-receptor 
antagonist. It is piperazine derivative and metabolite of hydroxyzine. Combinations of AMB 
with CTZ in drug formulation used as antihistaminic H1  blockers. Methylparaben and 
propylparaben are used as either single or in combinations in drug products as 
antimicrobial preservatives to prevent alteration of product preparations. Methylparaben is 
the methyl ester of p-hydroxybenzoic acid and propylparaben is the propyl ester of 
p-hydroxybenzoic acid.  
Liquid preparations are particularly susceptible to microbial growth because of the nature 
of their ingredients. Such preparations are protected by the addition of preservatives that 
prevent the alteration and degradation of the product formulation [2]. The finished product 
release specifications should include an identification test and a content determination test 
with acceptance criteria and  limits for each antimicrobial preservative present in the 
formulation [3]. The finished product self-life specification should also include an 
identification test and limits for the antimicrobial preservatives present [3]. Hence their (MP 
and PP) antimicrobial and antifungal properties make them an integral part of the product 
formulation. This encourages the development of new stability indicating method for 
simultaneous estimation of all compounds (AMB, CTZ, MP and PP) to provide driving 
force in today’s pharmaceutical industry. 
Several spectrophotometric methods have been reported for the qualitative and 
quantitative determination of AMB from pharmaceuticals formulations [4–7]. Various HPLC 
[8–11], GLC [12, 13], sequential injection technique coupled with monolithic column [14] 
LC-MS [15],  capillary electrophoretic [16] and by capillary electrophoresis and 
fluorescence detection [17] are also reported for its determination from biological fluids. 
Literature survey revealed that several spectrophotometric [18–20] methods, HPLC 
methods [21–24], HPLC coupled to tandem mass spectroscopy [25], capillary 
electrophoretic [26, 27] have been also reported for determination of CTZ from 
Pharmaceutical formulations and biological fluids. Detailed literature survey for MP and PP 
revealed that many existing analytical procedures are available in literature for the 
determination of present preservatives studied, either alone or in combination with other 
drugs by HPLC and other techniques [11, 28–36]. 
A detailed literature survey for AMB + CTZ revealed that few analytical methods are 
available using spectrophotometric and HPLC where; Neela M. Bhatia et al. [37], describe 
RP-HPLC and spectrophotometric estimation of AMB and CTZ in combined dosage form; 
Mukesh Maithani et al. [38], simultaneous estimation of AMB and CTZ in tablet dosage   A Rapid, Stability Indicating RP-UPLC Method for Simultaneous Determination of Ambroxol …  527 
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form by RP-HPLC method; Trivedi Aditya et al. [39], development of modified spectro-
photometric and HPLC method for simultaneous estimation of AMB and CTZ in tablet 
dosage forms; A. S. Birajdar et al. [40], simultaneous analysis of AMB with CTZ and of 
AMB with levo-Cetirizine dihydrochloride in solid dosage forms by RP-HPLC; NM Gowekar 
et al. [41], spectrophotometric estimation of AMB and CTZ from tablet dosage form. 
HPTLC method is also reported by S.B. Bagade et al. [42].  
UPLC is a new category of separation technique based upon well-established principles of 
liquid chromatography, which utilizes sub-2 µm particles for stationary phase. These 
particles operate at elevated mobile phase linear velocities to affect dramatic increase in 
resolution, sensitivity and speed of analysis. Owing to its speed and sensitivity, this 
technique is gaining considerable attention in recent years for pharmaceuticals and 
biomedical analysis. In the present work, this technology has been applied to the method 
development and validation study of assay determination (AMB, CTZ, MP and PP) in liquid 
pharmaceutical formulation.  
The combination of AMB and CTZ is not official in any pharmacopoeia. So far, no RP-
UPLC stability indicating method has been reported for the rapid simultaneous 
determination of AMB, CTZ, MP and PP in liquid pharmaceutical formulation. Therefore, it 
is necessary to develop a new rapid and stability-indicating method for simultaneous 
determination of four compounds (AMB, CTZ, MP and PP) in liquid pharmaceutical 
formulation. The proposed method is able to separates AMB, CTZ, MP and PP with each 
other and from its all twelve (AMB impurities A, B, C, D, E and CTZ impurities A, B, C, D, 
E, F, CDH1) known impurities/ degradation products  and one unknown degradation 
product  within 3.5 min.  Thereafter, this method was validated according to the ICH 
guideline [43] and successfully applied for separation and quantification of all compounds 
of interest in the liquid and solid pharmaceutical formulation.  
Ambroxol Impurity-A, B, C, D and E are official in British Pharmacopoeia [44]. Cetirizine 
specified impurities A, B, C, D, E and F are also official in British Pharmacopoeia [45]. 
Cetirizine CDH1 (impurity G as per British Pharmacopoeia) impurity is completely 
characterized in house (Dr. Reddy’s Laboratory) by using IR, Mass and NMR.  
Results and Discussion 
Method development and optimization 
The main objective of the RP-UPLC method development was to rapid and simultaneous 
determination of AMB, CTZ, MP and PP in liquid pharmaceutical formulation were: the 
method should be able to determine assay of four compounds in single run and should be 
accurate, reproducible, robust, stability indicating, filter compatible, linear, free of 
interference from blank / placebo / impurities / degradation products and straightforward 
enough for routine use in quality control laboratory. 
The spiked solution of AMB (120 µg/mL), CTZ (20 µg/mL), MP (40 µg/mL) and PP 
(4 µg/mL) was subjected to separation by RP-UPLC. Labeled claim of compounds and its 
working concentration is presented in Table 1. Initially the separation of all compounds 
was studied using water as a solvent-A and acetonitrile as a solvent-B on UPLC column 
(Eclipse Plus C18, RRHD, 50 x 2.1 mm; 1.8 µm) and Waters (UPLC) system with the 528  R. K. Trivedi, M. C. Patel and S. B Jadhav:   
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linear gradient program. The flow rate of 0.5 mL/min was selected with regards to the 
backpressure and analysis time as well. During this study column oven temperature was 
capped at 50°C. When study performed with above condition we observed broad peak of 
all the compounds. Various types of solvent-A and B were studied to optimize the method, 
which were summarized in Table 3 with the observation. Based on above solvent selection 
study optimized UPLC parameters were; flow rate 0.5 mL/min; column oven temperature 
50°C; gradient solvent program as per Table 2; 0.01M phosphate buffer in 0.1% 
triethylamine as a solvent-A and acetonitrile as a solvent-B. 
Ambroxol hydrochloride (AMB) 
trans-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride 
Br
N
H
OH
NH2
Br
H
Cl H
 
 
Cetirizine hydrochloride (CTZ); Cetirizine dihydrochloride 
(2-{4-[(4-Chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid (di)hydrochloride 
Cl H N
N O
OH
Cl
O
Cl H
   
Methylparaben (MP) 
Methyl 4-hydroxybenzoate 
O
O
O H  
 
Propylparaben (PP) 
Proppyl 4-hydroxybenzoate 
O
O
O H  
 
Fig. 1.  Chemical structures, UV spectrums and IUPAC name of AMB, CTZ, MP and PP 
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Tab. 1.  Formulation label claim with its working concentration (specification limit)  
Compd.  Formulation label claim per 5 mL 
Working concentration 
mg/mL  µg/mL 
AMB  Ambroxol hydrochloride 30 mg  0.12  120 
CTZ  Cetirizine hydrochloride 5 mg  0.02  20 
MP  Methylparaben 10 mg  0.04  40 
PP  Propylparaben 1 mg  0.004  4 
 
 
 
Fig. 2.  Overlay chromatograms of placebo, blank and spiked impurities along with 
analytes 
 
 
Fig. 3.  Overlay chromatograms of blank, placebo and sample preparation 530  R. K. Trivedi, M. C. Patel and S. B Jadhav:   
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In order to achieve symmetrical peak of all substances and more resolution between CTZ 
and PP different stationary phases were explored. Peak merging (CTZ and PP) was 
observed with Acquity BEH C8 (50 x 2.1 mm, 1.7µm) column. Poor resolution (RS=2.3 
between CTZ and PP) was observed with Acquity BEH C18 (50 x 2.1 mm, 1.7µm) column. 
Finally desired separation with symmetrical peaks was obtained using Eclipse Plus C18, 
RRHD (50 x 2.1mm, 1.8µm) column. Column oven temperature is also studied (at low 
temperature and 50°C) and found that 50°C is more appropriate with respect to separation 
and peak shape. Based on compounds UV spectrums 237nm was found more appropriate 
for the simultaneous determination. Chemical structures, UV spectrums and IUPAC name 
of AMB, CTZ, MP and PP are presented in Figure 1. AMB, CTZ, MP and PP are well 
resolved with each other and also well resolved with all twelve known impurities/ 
degradation products in reasonable time of 3.5 minutes which is presented in Figure 2. 
There was no any chromatography interference due to blank (diluent) and excipients 
(placebo) at the retention time of AMB, CTZ, MP and PP which was presented in Figure 3.  
Tab. 2.  Gradients program for elution 
Time (min)  Flow rate (mL/min)  % Solvent-A  % Solvent-B  Curve 
Initial  0.5  70  30  Isocratic 
0.2  0.5  70  30  Isocratic 
3.0  0.5  5  95  Linear 
3.1  0.5  70  30  Isocratic 
3.5  0.5  70  30  Equilibration 
 
Tab. 3.  Summary of solvent used to optimize the method  
Solvent-A  Solvent-B  Observation 
Retention time (tR)   USP tailing 
Water  Acetonitrile  AMB=0.947; MP=1.373 
CTZ=2.016; PP=2.748 
AMB=2.8; MP=2.0 
CTZ=2.5; PP=1.5 
0.1M KH2PO4  Acetonitrile  AMB=1.101; MP=1.451 
CTZ=2.234; PP=2.851 
AMB=1.8; MP=1.4 
CTZ=1.3; PP=1.3 
0.1M KH2PO4 buffer  
(pH 3.0 with H3PO4)   Acetonitrile  AMB=1.223; MP=1.477 
CTZ=2.019; PP=2.835 
AMB=1.7; MP=1.4 
CTZ=1.3; PP=1.2 
0.01M KH2PO4 + 0.1% 
triethylamine  Acetonitrile  AMB=2.185; MP=0.605 
CTZ=1.217; PP=1.389 
AMB=0.9; MP=1.3 
CTZ=1.0; PP=1.0 
USP = United state pharmacopoeia 
 
Analytical parameters and validation 
After satisfactory development of method it was subjected to method validation as per ICH 
guideline [43]. The method was validated to demonstrate that it is suitable for its intended 
purpose by the standard procedure to evaluate adequate validation characteristics (system 
suitability, accuracy, precision, linearity, robustness, solution stability, filter compatibility 
and stability indicating capability).    A Rapid, Stability Indicating RP-UPLC Method for Simultaneous Determination of Ambroxol …  531 
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Specificity  
Specificity is the ability of the method to measure the analyte response in the presence of 
its potential impurities [43]. Forced degradation studies were performed to demonstrate 
selectivity and stability indicating capability of the proposed RP-UPLC method. Figure 2 
and 3 are shows that there is no any interferences at the RT (retention time) of AMB, CTZ, 
MP and PP due to blank, placebo, impurities and degradation products.  
Degradation were observed when the drug product was subjected to acid hydrolysis (0.1N 
HCl, 60°C, 1h, Figure 4), base hydrolysis (0.1N NaOH, 60°C, 1h, Figure 5), oxidative (6% 
H2O2, 60°C, 1h, Figure 6), thermal (60°C, 1h, Figure 7) and photolytic degradation (1.2 
million Lux hours, Figure 8). Significant degradation was observed when the drug product 
was subjected to base hydrolysis leading to the formation of unknown impurity after the 
peak of MP, CTZ impurity-D, E and AMB impurity-B (Figure 5). Peaks due to AMB, CTZ, 
MP and PP were  investigated for spectral purity in the chromatogram of all exposed 
samples and found spectrally pure.  
 
Fig. 4.  Chromatogram of acid degraded drug product 
 
 
Fig. 5.  Chromatogram of base degraded drug product 532  R. K. Trivedi, M. C. Patel and S. B Jadhav:   
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Fig. 6.  Chromatogram of peroxide degraded drug product 
 
 
Fig. 7.  Chromatogram of heat degraded drug product 
 
 
Fig. 8.  Chromatogram of photolytic degraded drug product   A Rapid, Stability Indicating RP-UPLC Method for Simultaneous Determination of Ambroxol …  533 
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Precision 
Instrument precision: (Suitability of system)  
System suitability parameters were measured so as to verify the system performance. 
System precision was determined on six replicate injections of standard preparation 
(Table 1). All important characteristics including % RSD, resolution (between CTZ and 
PP), tailing factor and theoretical plate number were measured. The percentage RSD of 
area counts of six replicate injections was below 1.0 %, which indicates that the system is 
precise. The results obtained are shown in Table 4. The parameters all complied with the 
acceptance criteria and system suitability was established. 
Tab. 4.  System suitability results (precision and intermediate precision) 
Test  Parameters  MP  CTZ  PP  AMB  Proposed 
criteria 
Precision 
(n=6) 
USP resolution   –  –  4.34  -–  NLT 3.5 
USP tailing  1.3  1.0  1.0  0.9  NMT 1.5 
USP plate count  4549  24009  18630  33643  NLT 3000 
Area % RSD   0.2  0.2  0.4  0.1  NMT 2.0% 
Intermediate 
precision 
(n=6) 
USP resolution   –  –  4.35  –  NLT 3.5 
USP tailing  1.3  1.0  1.0  0.9  NMT 1.5 
USP plate count  4656  23951  18444  33537  NLT 3000 
Area % RSD   0.3  0.2  0.5  0.2  NMT 2.0% 
NLT= Not less than; NMT= Not more than. 
 
Method precision: (Repeatability)  
The precision of the assay method was evaluated by carrying out six independent 
determination of AMB, CTZ, MP and PP (120 µg/mL of AMB, 20 µg/mL of CTZ, 40 µg/mL 
of MP and 4 µg/mL of PP) test samples against qualified working standard. The method 
precision study shows the repeatability of the results obtained by the testing method. The 
% RSD (n=6) was 0.3 % for AMB, 0.5 % for CTZ, 0.4 % for MP and 0.7 % for PP, which 
are well within the acceptable limit of 2.0%. It was confirmed from results that the method 
is precise for the intended purpose (Table 5). 
Tab. 5.  Precision (n=6) and Intermediate precision (n=6) results 
Substance  Precision at 100%  Intermediate precision 
Mean % assay  % RSD  Mean % assay  % RSD 
AMB  101.1  0.3  101.0  0.4 
CTZ  99.3  0.5  99.5  0.6 
MP  98.1  0.4  98.3  0.7 
PP  97.5  0.7  97.2  0.9 
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Intermediate precision: (Reproducibility)  
The purpose of this study is to demonstrate the reliability of the test results with variations. 
The reproducibility was checked by analyzing the samples by different analyst using 
different chromatographic system and column on different day. The analysis was 
conducted in the same manner as the method precision and the % RSD of all six sets of 
sample preparations was determined (Table 5). The % RSD was 0.4 % for AMB, 0.6 % for 
CTZ, 0.7 % for MP and 0.9 % for PP, which are well within the acceptance criteria of 2.0%, 
so this study proved that the method to be rugged enough for day to day use.  
Accuracy 
The accuracy of an analytical method is the closeness of test results obtained by that 
method compared with the true values. To confirm the accuracy of the proposed method, 
recovery experiments were carried out by standard addition technique. The accuracy of 
the method was carried out by adding known amounts of each drug corresponding to three 
concentration levels; 50, 100, and 150% of the label claim (Table 1) along with the 
excipients in triplicate. The samples were given the same treatment as described in 
sample preparation. The percentage recoveries of AMB, CTZ, MP and PP at each level 
and each replicate were determined. The mean of percentage recoveries (n=3) and the 
relative standard deviation was calculated. The amount recovered was within ± 1.0 % of 
amount added, which indicates that there is no interference due to excipients present in 
liquid oral formulation. It was confirmed from results that the method is highly accurate 
(Table 6).  
Tab. 6.  Accuracy results 
Compd.  At 50% (n=3)  At 100% (n=3)  At 150% (n=3) 
%Recovery  %RSD  %Recovery  %RSD  %Recovery  %RSD 
AMB  100.1  0.3  99.8  0.2  99.8  0.2 
CTZ  99.7  0.4  99.9  0.3  100.2  0.2 
MP  100.2  0.3  99.8  0.2  99.7  0.2 
PP  100.6  0.5  100.4  0.4  99.6  0.6 
 
Linearity 
The linearity of an analytical method is its ability to elicit test results that are directly, or by 
a well-defined mathematical transformation, proportional to the concentration of analyte in 
sample within a given range. The nominal concentrations of standard and test solutions for 
AMB, CTZ, MP and PP were 120, 20, 40 and 4 µg/mL, respectively. The response function 
was determined by preparing standard solutions at seven different concentration levels 
ranging from 30.04–240.32 µg/mL for AMB, 5.01–40.08 µg/mL for CTZ, 9.97–79.76 µg/mL 
for MP and 1.005–8.04 µg/mL for PP (25 to 200% of analyte concentration). The response 
was found linear from 25% to 200% of standard concentration. For all compounds the 
correlation coefficient was greater than 0.999. The regression statistics are shown in 
Table 7.  
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Tab. 7.  Regression statistics 
Compd.  Linearity range 
(µg/mL) 
Correlation 
coefficient 
(r
2) 
Linearity (Equation)  Y- 
intercept 
bias in % 
AMB  30.04 to 240.32  0.9996  y = 9020.7497(x) + 6130.5328  0.557 
CTZ  5.01 to 40.08  0.9998  y = 11111.1220(x) – 263.1311  −0.117 
MP  9.97 to 79.76  0.9997  y = 18542.8499(x) + 5084.6885  0.676 
PP  1.005 to 8.04  0.9997  y = 16185.3682(x) − 118.5082  −0.181 
 
Lower limit of quantification (LLOQ) 
The signal-to-noise ratio (S/N) method was adopted for the determination of lower limit of 
quantification. The lower limit of quantification is estimated as ten times the S/N  ratio. 
Quantification limit was achieved by injecting a series of possible dilute solutions of AMB, 
CTZ, MP, and PP. The precision was also established at quantification level. The % RSD 
of peak area was well within the acceptance limit of not more than 10 %. The determined 
lower limit of qualification and precision at LLOQ values for AMB, CTZ, MP and PP are 
presented in Table 8.  
Tab. 8.  LLOQ and precision at LLOQ (n=6) results 
 
 
 
Robustness  
The robustness of an analytical procedure is a measure of its capacity to remain 
unaffected by small, but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. The effect of change in flow rate (± 0.05 
mL/min) and column oven temperature (± 5°C) on the retention time, resolution (between 
CTZ and PP), theoretical plates and tailing factor were studied. During study other 
chromatographic conditions were kept same as per the experimental section. It was 
conformed from results that the method is robust with respect to variability in above 
conditions (Table 9).  
Stability of sample in diluent 
Drug stability in pharmaceutical formulations is a function of storage conditions and 
chemical properties of the drug, preservative and its impurities. Condition used in stability 
experiments should reflect situations likely to be encountered during actual  sample 
handling and analysis. Stability data is required to show that the concentration and purity 
of analyte in the sample at the time of analysis corresponds to the concentration and purity 
of analyte at the time of sampling. Stability of sample solution was established by storage 
of sample solution at ambient temperature  (25°C)  for 24h. Sample solution was re-
analyzed after 12 and 24h time intervals and assay were determined for the compounds 
(AMB, CTZ, MP and PP) and compared against fresh sample. Sample solution did not 
show any appreciable change in assay value when stored at ambient temperature up to 
  MP  CTZ  PP  AMB 
LLOQ (µg/mL)  0.12  0.18  0.13  0.16 
Precision (% RSD)  3.5  4.3  5.7  4.8 536  R. K. Trivedi, M. C. Patel and S. B Jadhav:   
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24h, which are  presented in Table 10.  The results from solution stability experiments 
confirmed that sample solution was stable for up to 24h during assay determination.  
Tab. 9.  Robustness study results 
Condition  Parameters  MP  CTZ  PP  AMB  Proposed 
criteria 
Normal 
methodology 
USP resolution   –  –  4.34  –  NLT 3.5 
USP tailing  1.3  1.0  1.0  0.9  NMT 1.5 
USP plate count  4549  24009  18630  33643  NLT 3000 
Retention time in min  0.603  1.224  1.385  2.183  – 
At flow rate 
0.45 mL/min 
USP resolution   –  –  4.79  –  NLT 3.5 
USP tailing  1.3  1.0  1.0  0.9  NMT 1.5 
USP plate count  4657  24838  18993  34634  NLT 3000 
Retention time in min  0.667  1.309  1.498  2.319  – 
At flow rate 
0.55 mL/min 
USP resolution   –  –  3.88  –  NLT 3.5 
USP tailing  1.3  1.0  1.0  0.9  NMT 1.5 
USP plate count  4790  22386  17442  32067  NLT 3000 
Retention time in min  0.549  1.160  1.300  2.081  – 
At 45°C 
column oven 
temp. 
USP resolution   –  –  5.3  –  NLT 3.5 
USP tailing  1.3  1.0  1.0  0.9  NMT 1.5 
USP plate count  5310  23455  19314  32483  NLT 3000 
Retention time in min  0.628  1.224  1.434  2.186  – 
At 55°C 
column oven 
temp. 
USP resolution   –  –  3.6  –  NLT 3.5 
USP tailing  1.3  1.0  1.0  0.9  NMT 1.5 
USP plate count  4481  22939  16790  32440  NLT 3000 
Retention time in min  0.580  1.210  1.337  2.172  – 
 
Tab. 10.  Solution stability results 
Time intervals  AMB  CTZ  MP  PP 
% Assay Initial  100.7  99.5  98.0  97.6 
% Assay after 12h  100.3  99.6  98.2  97.7 
% Assay after 24h  100.4  99.3  98.1  97.4 
 
Filter compatibility 
Filter compatibility was performed for nylon 0.22 µm syringe filter (Pall Life sciences) and 
PVDF 0.22  µm syringe filter (Millipore). To confirm the filter compatibility in proposed 
analytical  method, filtration recovery experiment was carried out by sample filtration 
technique. Sample was filtered through both syringe filters  and percentage assay was 
determined and compared against centrifuged sample. Sample solution was not showing 
any significant changes in assay percentage with respect to centrifuged  sample. 
Percentage assay results are presented in Table 11. In displayed result difference in % 
assay was not observed more than ±0.5, which indicates that both syringe filters having a 
good compatibility with sample solution.   A Rapid, Stability Indicating RP-UPLC Method for Simultaneous Determination of Ambroxol …  537 
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Tab. 11.  Filter compatibility results (Assay % w/w) 
Compd.  Centrifuged  PVDF filter 0.22µm 
(Millipore) 
Nylon filter 0.22µm 
(Pall Life Sciences) 
AMB  100.5  100.3  100.3 
CTZ  99.7  99.5  99.4 
MP  98.3  98.3  98.5 
PP  97.5  97.6  97.3 
 
Application of the method to dosage forms 
The present method was applied for the estimation of drugs and preservatives in the 
commercially available various dosage forms. The results obtained are as shown in Table 
12. Based on obtained results developed method is suitable for the various marketed 
dosage forms. Developed method also proved the suitability for preservatives 
determination in various liquid dosage forms.  
Tab. 12.  Results of market products (mg/ 5 mL for syrup and mg/ tablets for tablets) 
Product Name and  
Labeled claim (in mg) 
AMB  CTZ  MP  PP  LCTZ 
ZyrCold Syrup [AMB(30); CTZ(2.5)]  29.8  2.47  9.53  0.94  N.A. 
Relent Syrup [AMB(30); CTZ(2.5)]  30.1  2.48  10.10  1.01  N.A. 
ZyrCold Tablets [AMB(30); CTZ(2.5)]  29.7  2.46  N.A.  N.A.  N.A. 
Cetzine Tablets [CTZ(10)]  N.A.  9.93  N.A.  N.A.  N.A. 
DOI-1 Tablets [CTZ(10)]  N.A.  9.72  N.A.  N.A.  N.A. 
Xyzal Syrup [LCTZ (2.5)]  N.A.  N.A.  10.5  1.07  2.51 
N.A. not applicable 
 
Experimental 
Materials and Reagents  
Drug product, placebo solution, working standards and reference standards were provided 
by Dr. Reddy’s laboratories Ltd., Hyderabad, India. HPLC grade acetonitrile and methanol 
were obtained from J.T.Baker (NJ., USA). GR grade potassium dihydrogen phosphate, GR 
grade orhtophosphoric acid and GR grade triethylamine were obtained from Merck Ltd. 
(Mumbai, India). 0.22 µm nylon membrane filter and nylon syringe filters were purchased 
from  Pall life science limited (India). 0.22 µm PVDF syringe filter was purchased from 
Millipore (India). High purity water was generated by using Milli-Q Plus water purification 
system (Millipore
®, Milford, MA, USA).  
Equipments 
Cintex digital water bath was used for specificity study. Photo stability studies were carried 
out in a photo-stability chamber (SUNTEST XLS+, ATLAS, Germany). Thermal stability 
studies were performed in a dry air oven (Cintex, Mumbai, India). 538  R. K. Trivedi, M. C. Patel and S. B Jadhav:   
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Chromatographic conditions 
Analyses were performed on Acquity UPLC
TM system (Waters, Milford, USA), consisting of 
a binary solvent manager, sample manager and PDA (photo diode array) detector. System 
control, data collection and data processing were accomplished using Waters Empower
TM-
2 chromatography data software. The chromatographic condition was optimized using 
Agilent Eclipse Plus C18, RRHD 1.8 µm (50 mm x 2.1 mm) column. Mixture of 0.01M 
phosphate buffer (KH2PO4) in 0.1% triethylamine was used as a solvent-A and acetonitrile 
was used as solvent-B. Solvents-A and B was filtered through 0.22 µm nylon membrane 
filter and degassed under vacuum prior to use. The separation of AMB, CTZ, MP, PP and 
all impurities was achieved by gradient elution using solvent-A and B (Table 2). Mixture of 
water and methanol in the ratio of 50:50 (v/v) respectively was used as a diluent. The 
finally selected and optimized conditions were as follows: injection volume 4 µL, gradient 
elution (Table 2), at a flow rate of 0.5 mL/min at 50°C (column oven) temperature, 
detection wavelength 237 nm. Under these conditions, the backpressure in the system 
was about 6,000 psi. The stress degraded samples and the solution stability samples were 
analyzed using a PDA detector covering the range of 200-400nm.  
Standard solution preparation  
Standard solution was prepared by dissolving standard substances in diluent to obtain 
solution containing  120  µg/mL of Ambroxol hydrochloride, 20  µg/mL of Cetirizine 
hydrochloride, 40 µg/mL of Methylparaben and 4 µg/mL of Propylparaben.  
Sample solution preparation 
An accurately weighed 2 gm of sample solution was taken into the 100 mL volumetric 
flask.  About  70  mL of diluent was added to this volumetric flask and sonicated in an 
ultrasonic bath for 5 min. This solution was then diluted up to the mark with diluent and 
mixed well. It was then filtered through 0.22 µm PVDF syringe filter and the filtrate was 
collected after discarding first few milliliters. 
Placebo (other substances without AMB, CTZ, MP and PP) solution preparation 
An accurately weighed 2 gm of placebo solution was taken into the 100 mL volumetric 
flask.  About  70  mL of diluent was added to this volumetric flask and sonicated in an 
ultrasonic bath for 5 min. This solution was then diluted up to the mark with diluent and 
mixed well. It was then filtered through 0.22 µm PVDF syringe filter and the filtrate was 
collected after discarding first few milliliters. 
Market product sample solution preparation (for oral solution) 
An accurately weighed X gm of sample solution was taken into 100 mL volumetric flask 
(where X= 4 gm for Xyzal
® [UCB, India Pvt. Ltd.; B.No.-VO 10001], 2 gm of ZyrCold
® 
[UCB, India Pvt. Ltd.; B.No.-LI10035] and 2 gm of Relent
® [Dr. Reddy’s Lab. Ltd. India; 
B.No.-L 0590]). About 70 mL of diluent was added to this volumetric flask and sonicated in 
an ultrasonic bath for 3 min. This solution was then diluted up to the mark with diluent and 
mixed well. It was then filtered through 0.22 µm PVDF syringe filter and the filtrate was 
collected after discarding first few milliliters. 
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Market product sample solution preparation (for oral tablet) 
Twenty tablets were crushed to fine powder. An accurately weighed portion of the powder 
equivalent to 5 mg of CTZ was taken into 100 mL volumetric flask (Cetzine
® Tablets [GSK 
Pharmaceuticals Ltd.; B.No.-L473], Dio-1
® Tablets [Unison pharmaceuticals; B.No.-2005] 
and ZyrCold
® Tablets [UCB, India Pvt. Ltd.; B.No.-5829]). About 70 mL of diluent was 
added to this volumetric flask and sonicated in an ultrasonic bath for 15 min. This solution 
was then diluted up to the mark with diluent and mixed well. It was then filtered through 
0.22  µm PVDF syringe filter and the filtrate was collected after discarding first few 
milliliters. 
Conclusion 
A gradient RP-UPLC method was successfully developed for the simultaneous estimation 
of AMB, CTZ, MP and PP in liquid pharmaceutical formulation. The developed method is 
selective, precise, accurate, linear, filter compatible and robust. Forced degradation data 
proved that the method is specific for the analytes and free from the interference  of 
placebo / known impurities / degradation products and unknown degradation products. 
The run time (3.5 min) enables for rapid determination of drugs and preservatives. 
Moreover, it may be applied for individual and simultaneous determination of AMB, CTZ, 
LCTZ, MP and PP compound in pharmaceutical drug product and substance. Also it can 
be utilized for determination of assay, blend uniformity and content uniformity of 
pharmaceutical products (CTZ tablets and AMB+CTZ tablets), where sample load is higher 
and high throughput is essential for faster delivery of results.  
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